FDA OKs expanded label for AbbVie's Mavyret

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

The FDA has approved the use of AbbVie's (ABBV -1.1%) Mavyret (glecaprevir and pibrentasvir) for the treatment of all six genotypes of hepatitis C virus (HCV) in young people ages 12 - 17 years old.

The agency first approved Mavyret in August 2017 for HCV-positive adults.

Subscribe for full text news in your inbox